Smith Brendan 4
4 · CRISPR Therapeutics AG · Filed Oct 18, 2021
Insider Transaction Report
Form 4
Smith Brendan
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-10-14+90,000→ 90,000 totalExercise: $98.70Exp: 2031-10-14→ Common Shares (90,000 underlying) - Award
Restricted Stock Units
2021-10-14+15,000→ 15,000 total→ Common Shares (15,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]This restricted stock unit award was granted on October 14, 2021 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on October 14, 2022, (ii) one quarter of the shares vesting on October 14, 2023, (iii) one quarter of the shares vesting on October 14, 2024, and (iv) one quarter of the shares vesting on October 14, 2025.
- [F3]This option was granted on October 14, 2021 with respect to 90,000 Common Shares, with 25% of the shares vesting on October 14, 2022 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.